Aldehyde dehydrogenases (ALDH) catalyze the irreversible oxidation of aldehydes to their corresponding carboxylic acid. Alterations in ALDH1A1 activity are associated with such diverse diseases as cancer, Parkinson's disease, obesity, and cataracts. Inhibitors of ALDH1A1 could aid in illuminating the role of this enzyme in disease processes. However, there are no commercially available selective inhibitors for ALDH1A1. Here we characterize two distinct chemical classes of inhibitors that are selective for human ALDH1A1 compared to eight other ALDH isoenzymes. The prototypical members of each structural class, CM026 and CM037, exhibit sub-micromolar inhibition constants, but have different mechanisms of inhibition. The crystal structures of these compounds bound to ALDH1A1 demonstrate that they bind within the aldehyde binding pocket of ALDH1A1 and exploit the presence of a unique Glycine residue to achieve their selectivity. These two novel and selective ALDH1A1 inhibitors may serve as chemical tools to better understand the contributions of ALDH1A1 to normal biology and to disease states.
INTRODUCTION
Aldehydes are highly reactive compounds that can lead to cellular toxicity through their ability to form adducts with a variety of cellular nucleophiles found in proteins, nucleic acids, as well as small molecule metabolites. In humans, aldehyde detoxication occurs via three main enzyme systems: aldehyde oxidases, aldo-keto reductases, and aldehyde dehydrogenases. The human genome contains at least 19 functional genes for aldehyde dehydrogenases (ALDH) that catalyze the NAD(P) + -dependent oxidation of endogenous and exogenous aldehydes to their corresponding carboxylic acids or CoA esters. ALDHs differ in their tissue distribution, subcellular location, structure, as well as preferred substrates and are critical enzymes that contribute to numerous biological functions as well as to the cellular defense against aldehyde toxicity 1 . They are involved in the synthesis of critical carboxylic acids including retinoic acid, a key regulator of cell growth and development 2 , and the neurotransmitter, γ-aminobutyric acid 3 . A major role of the ALDH superfamily is protection from aldehyde-induced cytotoxicity 1 . Oxidative stress often results in lipid peroxidation, generating over 200 aldehydes, including 4-hydroxyhexenal, 4-hydroxynonenal, and malondialdehyde 4 . These endogenously generated compounds can carbonylate proteins and have been associated with neurodegenerative disorders 5 and aging 6 . A variety of drugs, including ethanol and the anticancer drug cyclophosphamide, are metabolized via ALDH-dependent pathways 7 . In the environment, although some aldehydes have non-anthropogenic sources, motor vehicle exhaust, industrial applications, cigarette smoke and other human activities are the primary sources for exogenous aldehydes, including formaldehyde, acetaldehyde, and acrolein 8 .
As a consequence of their critical contributions to aldehyde metabolism, loss of function mutations in ALDH genes are linked to a number of diseases. ALDH2 is the primary enzyme involved in the oxidation of acetaldehyde during ethanol metabolism 9 and a single nucleotide polymorphism (SNP) results in an enzymatically crippled protein (ALDH2*2), in which acetaldehyde, derived from ethanol oxidation, accumulates and induces alcohol toxicity 10, 11 . Alterations in ALDH1A1 and ALDH2 expression or activity may play a role in Parkinson's Disease through the metabolism of the neurotransmitter dopamine, leading to increased levels of neurotoxic aldehydes, including 3,4-dihydroxyphenylacetaldehyde 12 .
Modulation of ALDH2's role in dopamine metabolism has been shown to affect cocaine seeking behavior 13 . Mutations in ALDH3A2 lead to Sjögren-Larsson Syndrome, which is characterized by mental retardation, icthyosis, and spastic tetraplegia due to impaired metabolic clearance of sphingosine and plasmalogen metabolites 14, 15 . Mutations in other ALDH genes have been linked to pyridoxine-dependent epilepsy (ALDH7A1) 16 , type II hyperprolinemia resulting in mental retardation and seizures (ALDH4A1 and ALDH18A1) 17, 18 , and may possibly contribute to paranoid schizophrenia (ALDH3B1) 19 . A number of ALDHs have been associated with cancer and/or cancer stem cells, including ALDH1A1, ALDH1A2, ALDH1A3, ALDH1L1, ALDH2, ALDH3A1, ALDH4A1, and ALDH7A1 7, 20 . Both ALDH1A1 and ALDH3A1 detoxify some oxazaphosphorine anticancer drugs and decrease the drug's effectiveness 21, 22 . ALDH4A1 is p53-inducible and may minimize cellular damage due to oxidative stress 23 . ALDH1A2 is a possible tumor suppressor gene in prostate cancer, likely via the enzyme's role in retinoid metabolism 24 . The ALDH2*2 mutation has also been associated with a variety of cancers, possibly due to increased aldehyde-induced DNA damage 25, 26 . Up-regulation of ALDH activity is also common in both normal and cancer stem cells 20 . Therefore, ALDH is considered a stem cell biomarker and the ALDEFLUOR assay (Stemcell Technologies, Vancouver, Canada) uses this ALDH activity as a means to identify cancer stem cells 27 . ALDH1A1 (retinaldehyde dehydrogenase 1, RALDH1) is a highly conserved, cytosolic homo-tetramer (~55 kDa monomers) that is widely expressed and found in numerous tissues, including brain, liver, kidneys, adipose, eye lens and retina. A key role of ALDH1A1 is the oxidation of retinaldehyde to retinoic acid (RA), forming transcriptional regulators critical for normal cell growth and differentiation 28 . Both the substrate (retinaldehyde) and product (RA) are important for normal biological processes, including vision, cellular differentiation, and immune function 7 . ALDH1A1 shares greater than 70% sequence identity to both ALDH1A2 and ALDH1A3 (RALDH2 and RALDH3, respectfully) and both also convert retinaldehyde to RA, but their roles may be more confined to embryogenesis and stem cell development 29, 30 . ALDH1A1 knockout mice are viable, but ALDH1A2 and ALDH1A3 knockout mice are lethal early in development or shortly after birth 30 . In addition to its similarity with other retinaldehyde dehydrogenases, ALDH1A1 also shares nearly 70% sequence identity to the mitochondrial ALDH2 and ALDH1B1 enzymes, but shares less than 50% sequence identity with members of other ALDH families, including ALDH3A1, ALDH4A1 and ALDH5A1.
The structure of mammalian ALDHs are similar, functioning as homomultimers, and each monomer contains three structural domains: a catalytic domain, a cofactor binding domain, and an oligomerization domain 31 . The global structural similarities support identical active site residues whose contributions to aldehyde oxidation are well established. In addition to aldehyde oxidation activity, some ALDHs, including ALDH1A1, also possess an NAD + -independent esterase activity 32 and this esterase activity uses the same active site residues as does the dehydrogenase activity 33 . Despite similarities in structure and function, as well as some overlap in substrate preferences, the isoenzymes of the ALDH family of proteins have evolved different aldehyde binding sites due to substitutions of the residues lining their respective substrate binding tunnels 31, 34 . These differences have allowed for the development of activators and inhibitors of various isoenzymes as therapeutics. For example, disulfiram (commercial: Antabuse) is an inhibitor of both ALDH1A1 and ALDH2, and this drug can be used to treat alcoholism 31 and potentially for cocaine addiction 13 . Alda-1 is a selective activator of ALDH2 and may offer cardiac protection following ischemic events by decreasing cytotoxic aldehyde levels 35 . Since multiple cancers have increased ALDH1A1 and/or ALDH3A1 activity leading to increased resistance to chemotherapeutic agents, selective inhibitors of these two isoenzymes are also of interest 36, 37 .
Available inhibitors of ALDHs have been recently reviewed 31 . At this time, there are no commercially available inhibitors capable of distinguishing between ALDH1A1 and the other highly similar ALDH isoenzymes, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH2. For instance, the control inhibitor used in the ALDEFLUOR assay, diethylaminobenzaldehyde (DEAB), is an effective inhibitor of at least three of these isoenzymes 38, 39 . From a high-throughput screen (HTS) 40 , we have identified two classes of ALDH1A1 inhibitors and have determined the structural and kinetic basis for their selectivity toward ALDH1A1.
RESULTS
Since the esterase and dehydrogenase activity of ALDH1A1 utilize similar active site residues, modulators of esterase function as convenient surrogates for the dehydrogenase activity, as has been shown previously with the discovery of ALDH3A1 inhibitors 36 . The esterase assay was selected for the screening assay instead of aldehyde oxidation to: 1.) minimize spectral overlap with the absorbance characteristic of the compounds in the library, and 2.) eliminate compounds that compete with structurally conserved elements of the cofactor binding site. CM026 and CM037 emerged from the HTS as esterase modulators of ALDH1A1 40 . CM026 ( Figure 1A ) has a molecular weight of 442.5 Daltons and CM037 ( Figure 2A ) has a molecular weight of 431.6 Daltons. These compounds have no structural similarity to any known, commercially available aldehyde dehydrogenase modulators.
Kinetic characterization of CM026 and CM037
CM026 is a selective inhibitor for ALDH1A1 versus eight other ALDH isoenzymes examined. At a concentration of 20 µM, CM026 had no effect on seven other human ALDH isoenzymes (ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH4A1, ALDH5A1) as well as the carboxyl-terminal ALDH domain of rat ALDH1L1 ( Figure 1B ). At a concentration of 100 µM, CM026 modestly increased aldehyde oxidation catalyzed by ALDH1A2, ALDH1A3, and ALDH1B1. CM026 has good potency toward ALDH1A1 (IC 50 of 0.80 ± 0.06 µM 40 , Figure 1C ) for an initial hit compound. Complete inhibition of ALDH1A1 was not observed. CM026 has a noncompetitive partial mode of inhibition with respect to varied acetaldehyde, with a K i of 0.80 ± 0.16 µM and β = 0.15 ± 0.03, indicating maximum inhibition at 0.15(V max ) ( Figure 1D ). CM026 had an uncompetitive partial mode of inhibition with respect to varied NAD + and exhibited a K i of 0.72 ± 0.03 µM and β = 0.10 ± 0.03 ( Figure 1E ).
It is possible that the size of the R-groups attached to the xanthine ring influences whether it is possible to slowly bind and release small aldehydes at the catalytic nucleophile, such substrate length dependency was also observed with the activator Alda-1 in ALDH2 41 . Figure 2A ) was also selective for ALDH1A1 at 20 µM versus eight other ALDH isoenzymes tested ( Figure 2B ). While 20 µM CM037 had little effect on most ALDH isoenzymes tested, ALDH1A3 was inhibited approximately 20% at this concentration. Higher concentrations were not tested due to solubility limits of CM037 under these assay conditions. CM037 exhibits an IC 50 = 4.6 ± 0.8 µM toward ALDH1A1 versus the substrate propionaldehyde ( Figure 2C ) and a competitive mode of inhibition with respect to varied substrate acetaldehyde and an average K i of 0.23 ± 0.06 µM from three independent inhibition experiments 42 .
CM037 (

Structure Activity Relationship for Analogs of CM026
There were 77 compounds in the initial screening hit list that were structurally similar to CM026 40 . We have tested 17 members of this compound class and they exhibit good selectivity for ALDH1A1 compared to ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 (Table 1 ). At high concentrations (100 µM), some compounds activated the aldehyde oxidation activity of other ALDH1 enzymes tested (eg. CM026), but in most cases these effects were observed as the solubility limit of the compounds in the assay system were approached, precluding a full dose-response study. At 20 µM, none of the compounds demonstrated activation exceeding 10% of control activity, suggesting any activation is of modest potency and not likely to impact these enzyme activities in vivo. These compounds share a common xanthine core structure with theophylline and caffeine, but neither of these stimulants affected ALDH1A1 activity at concentrations up to 250 µM, indicating that substituents at the R1 and R2 positions are necessary for ALDH1A1 inhibition (Table 1) . Halogens on either R-group were not tolerated. CM053 was the most potent analog examined, with an IC 50 = 210 ± 40 nM and a K i = 96 ± 14 nM with noncompetitive tight mode of inhibition compared to varied substrate acetaldehyde ( Figure 3 ). CM028 shares the same R2 group as CM053 but the isopentyl group at R1 has been replaced with a phenylpropyl group. CM028 is less potent, with an IC 50 = 2.0 ± 0.1 µM, and exhibits a K i = 240 ± 40 nM with competitive tight mode of inhibition. The lower potency suggests that the phenylpropyl group might present steric conflicts not found with the smaller phenyl and isopentyl groups (Table 1) . Unlike CM026, CM028 and CM053 demonstrated complete inhibition, which confirms that the nature of the R1 group alone does not influence the final extent of inhibition, since both CM026 and CM053 share the same R1 group.
Crystal Structure of ALDH1A1 Complexed with CM026, CM053 and CM037
To determine the mechanism that underlies the ability of these compounds to selectively inhibit ALDH1A1, we used X-ray crystallography to determine the structure of the enzymecompound complexes. We solved the crystal structures of human ALDH1A1 in complexes with CM026, CM053, and CM037 to resolutions between 1.80 Å and 1.95 Å ( Table 2 ). For CM026 and CM037, the naturally occurring N121S polymorphic variant of ALDH1A1 was used 40 , while wtALDH1A1 was used for the structure with bound CM053. A comparison of the respective alpha carbons in the structure of the N121S·CM026 to those in the WT·CM053 generated an RMSD of 0.12Å, indicating a high degree of similarity between WT and the N121S mutant as expected since the two have very similar kinetic behavior 40 . CM026 binds near the solvent exposed exit of the substrate-binding site ( Figure 4 ). The xanthine rings for both CM026 and CM053 are parallel to and approximately 3.6 Å from Tyr297, with which it interacts via hydrophobic pi-stacking interactions. Four residues form hydrogen bonds with CM026; the xanthine ring interacts with His293, Cys302, and Gly458, while Trp178 interacts with the ketone group on R2. The isopentyl group of R1 projects towards Cys303 and fills much of the hydrophobic space bounded by Phe171 and Phe466. CM053 differs from CM026 only in its R2 group, which can form hydrogen bonds with two residues, Trp178 and Val460 ( Figure 5 ). CM037 binds at a similar location to the CM026 compounds, but its long axis is oriented almost orthogonal to that of CM026 and CM053 ( Figure 6A ). Most of the tricyclic ring of CM037 is in a hydrophobic pocket formed by Phe171, Val460, and Phe466 with a potential hydrogen bond between the ring system's carbonyl oxygen atom and the side chain of Cys302 ( Figure 6B ). The biggest structural adaptation to CM037 binding is the movement of Trp178 away from the substrate-binding site to accommodate the benzyl ring of CM037 ( Figure 6C ). This conformational movement appears to be dynamic and impacts the observed electron density for both the benzyl group of CM037 and of Trp178. Trp178 is well ordered in all other structures determined of human ALDH1A, including our CM026 and CM053 structures, but has weak density for the benzyl moiety of the indole ring in this complex ( Figure 6D ). We would suggest that optimization of CM037 could be achieved by altering the thiophene and benzyl ring systems to alleviate these steric conflicts. To better understand the selectivity of these compounds for ALDH1A1, we compared these structures against human ALDH2 (PDB code 1CW3 43 ), ALDH3A1 (PDB code 3SZA 37 ), and ALDH4A1 (PDB code 3V9G 44 ) and identified a critical glycine (Gly458) that is present near the xanthine ring binding site in ALDH1A1. This glycine is replaced by larger amino acid side chains in the other three human structures examined, as well as in sheep ALDH1A1 (PDB Code 1BXS 45 ). In rat ALDH1A2 (PDB code 1BI9 46 ), which shares 97% sequence identity to human ALDH1A2, this location is part of a small disordered loop not observed in the crystal structure 46 . Using sequence alignments of the human genes, Gly458 in ALDH1A1 is replaced by an asparagine in ALDH1A2, ALDH1A3, and ALDH1B1, an aspartate in ALDH2, and an isoleucine in ALDH3A1 ( Figure 7A ). As shown in Figure 7B , these side chains would interfere with the position of the xanthine ring, effectively eliminating the ability of these analogs to bind to any isoenzyme but ALDH1A1.
Characterization of ALDH1A1 G458N Mutant
To confirm whether Gly458 in ALDH1A1 directly impacts the selectivity of the CM026 analogs and CM037 for ALDH1A1, we mutated the glycine at this position to asparagine, as found in ALDH1A2 and ALDH1A3. We determined the kinetic parameters for acetaldehyde oxidation for both the wild-type and G458N enzymes (Table 3 ). This mutation did not dramatically affect the enzyme's catalytic efficiency for aldehyde oxidation. However, when Gly458 is mutated to asparagine, CM026 no longer inhibits the enzyme at concentrations up to 100 µM and none of the CM026 analogs inhibited the mutant more than 25% (Figure 8) . Similarly, 20 µM CM037 no longer inhibited the G458N enzyme. However, the nonselective inhibitors DEAB and CM302 40 both inhibit G458N, with IC 50 values of 0.52 ± 0.10 µM and 3.1 ± 0.3 µM respectively 39, 40 (Table 3 ). These data support the hypothesis that the substrate-binding site, and in particular Gly458, determines the selectivity of both the CM026 and CM037 classes of compounds for ALDH1A1, and that bulkier side chains at this position in ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 occludes their binding to these ALDH isoenzymes.
DISCUSION AND CONCLUSIONS
Aldehyde dehydrogenases contribute to a variety of biological processes and disease states. ALDH1A1, in particular, has been linked to such diverse diseases as cancer, Parkinson's disease, obesity, and cataracts. Therefore, selective inhibitors of ALDH1A1 would be of tremendous value to understanding the roles of this enzyme in both normal and disease processes. However, great structural and functional similarity exists, especially within the ALDH1 family, with five members sharing approximately 70% protein sequence identity or higher, plus significant overlap in substrate utilization. To date, there are no ALDH1A1-selective inhibitors commercially available. Although comparisons of available ALDH structures indicate a high degree of overlap, there exist distinct surface topographies that may enable development of selective inhibitors ( Figure 9 ). ALDH1A1 possesses a wider opening leading to the active site, whereas ALDH2 has a much more constricted, cylindrical shaped site. ALDH3A1 possesses a wider inner vestibule near the catalytic nucleophile, with a much narrower and curved entryway. The narrower entries in ALDH2 and ALDH3A1 eliminate the binding site for the CM026 and CM037 classes of inhibitors in large part due to the side chain present at the position equivalent to Gly458. ALDH4A1 possess a serine at the position equivalent to Gly458. However the loop structure in which it resides is different enough from ALDH1A1 to prevent compound binding. Similar to daidzin, both the CM026 and CM037 classes of compounds are planar, multi-ringed structures that adopt binding modes that take advantage of the topological characteristics unique to the ALDH isoenzyme toward which they demonstrate selectivity and neither of these new compounds can be accommodated in the restricted substrate binding sites of ALDH3A1 or ALDH2. Daidzin is a strong inhibitor of ALDH2 but it also inhibits ALDH1A1 47 . Daidzin binds in a similar location to CM026, but comparison of the structure of ALDH1A1 and ALDH2 (PDB 2VLE 48 ) bound to these respective compounds shows that the two compounds bind nearly perpendicular to each other in their respective binding modes. In particular, aligning the ALDH2-daidzin structure to ALDH1A1 demonstrates that daidzin binding need not engage ALDH1A1 near its unique G458 site ( Figure 10 ). As discussed by Lowe et al, the tighter binding pocket of ALDH2 compared to ALDH1A1 favors more intimate interactions between the ALDH2 and daidzin, increasing specificity 48 . CM026 exploits a binding pocket that is not accessible in other ALDH isoenzymes due to their larger amino acid side chains at position 458.
In contrast to CM026, the directionality of CM037 binding within the ALDH1A1 active site resembles that of daidzin in ALDH2. However, the 4-oxo group and the branched structure of CM037 near the exit of the substrate binding site exploits the same G458 region for selectivity. Our structural studies identified Gly458 as a major contributor to the selectivity of the CM026 and CM037. Sequence alignments of the other 18 human ALDH isoenzymes indicate that the only other family member with a glycine in this position is ALDH16A1. However, the function of ALDH16A1 is unknown and has a three residue deletion in the active site loop which eliminates the conserved Cys nucleophile, suggesting this protein may have functions that are independent of aldehyde dehydrogenase activity 49 . The presence of a non-glycine residue at this position does not adversely affect catalytic activity toward small substrates or inhibition by the non-selective compounds, DEAB and CM302. Consequently, these compounds identified via an esterase-based high throughput screen successfully exploited a unique structural feature found primarily in primate ALDH1A1 enzymes, which further validates the use of the esterase activity as a screening tool for ALDH isoenzymes 40 .
Selective inhibitors of ALDH1A1 are needed to understand the role of this enzyme in both normal and disease processes. As recently reviewed by Ma and Allan, a number of ALDH family members have been associated with both normal stem cells and cancer stem cells 20 . The viability of the ALDH1A1-/-mice suggests that ALDH1A1 is non-essential or can be compensated for by other family members during growth and development 50 . On the other hand, ALDH1A1 is considered a biomarker for lung 51 , ovarian 52 , prostate 53 and a number of other cancers. Ovarian cancer cells form spheroids, cellular aggregates that aid metastasis 54 . Recently ALDH1A1 was shown to be upregulated in ovarian cancer spheroids 42 . This study utilized our ALDH1A1-selective compound CM037 (published as A37) to disrupt spheroid formation and reduce cell viability, supporting the hypothesis that ALDH1A1 could serve as a target to improve cancer outcomes 42 . ALDH1A1 and ALDH3A1 are both involved in the metabolism of the cancer drug cyclophosphamide, metabolizing the active compound to a less active form and contributing to drug resistance. ALDH3A1 inhibitors have been shown to increase sensitivity to the cyclophosphamide analog mafosphamide when combined in cell lines with high ALDH3A1 expression 55, 56 . ALDH1A1 could serve as a similar target to minimize cyclophosphamide resistance in cancers with high ALDH1A1 levels. The functional role that ALDH1A1 contributes to stem cells and cancer metastasis is not understood. However, the discovery of these two novel classes of selective ALDH1A1 inhibitors may serve as chemical tools to uncover those roles in both normal and diseased cells.
EXPERIMENTAL SECTION Materials
Reagents, including acetaldehyde, propionaldehyde, para-nitrophenylacetate, NAD + , and buffers were all purchased from Sigma Aldrich unless otherwise noted. Compounds were purchased from ChemDiv Corp. (San Diego, CA) and were >95% pure based on the NMR spectra provided by the vendor. Following receipt from the vendor, their chemical identities were further verified by LC/MS in the Department of Chemistry, Indiana University-Purdue University Indianapolis and used without further purification.
ALDH expression and purification
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 were produced and purified as previously described 36, 56, 57 . The ALDH1A1 protein used for the ALDH1A1-CM026 crystal contained an Asn-to-Ser SNP at residue 121 40, 58 . Unless where noted otherwise, ALDH1A1 WT protein was used for all aldehyde oxidation assays and for the ALDH1A1-CM053 structure. The full length cDNA for human ALDH4A1 and ALDH5A1 were generously provided by Daria Mochly-Rosen. ALDH4A1 was subcloned into the pET-28a expression plasmid and ALDH5A1 was in pTrcHis-Topo. The carboxyl terminal ALDH domain of rat ALDH1L1 was generously provided by Sergey Krupenko in the pRSET expression plasmid. ALDH1L1, ALDH4A1, and ALDH5A1 were expressed and purified as previously described for ALDH3A1 36 with the following modifications: 1) for ALDH1L1 and ALDH5A1 the medium contained 100 µg/mL ampicillin, 2) cells were lysed via 3 passages through a microfluidizer (DivTech Equipment), and 3) a single passage on a nickel-NTA column was used for purification, without the second Q-sepharose column used to purify ALDH3A1. Purified enzymes used for kinetics were stored at −80°C. ALDH1A1 used for crystallization was stored at −20°C in a 50% (v/v) solution with glycerol and dialyzed against 10 mM Na + -ACES pH 6.6 and 1 mM dithiothreitol at 4°C.
Generation of wild-type ALDH1A1 and the G458N mutant
The QuikChange site-directed mutagenesis protocol was used to make point mutations. First, wtALDH1A1 was generated from the Weiner N121S polymorphism as previously described 40 . A point mutation of wtALDH1A1 was performed to produce the G458N mutant. The ALDH1A1 G458N mutant was constructed using the forward primer 5'-GTG GGT GAA TTG CTA TAA CGT GGT AAG TGC CCAG-3' and its complement. This G458N mutant was purified in the same way as other ALDH1A1 proteins (WT, N121S). G458N was stored at 2-mg/mL and 8-mg/mL at −80°C. Kinetic experiments for G458N were performed in the same manner as WT protein.
Aldehyde dehydrogenase activity assay
Dehydrogenase activity of purified recombinant ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 was assayed spectrophotometrically by monitoring the formation of NADH at 340 nm (molar extinction coefficient of 6220 M −1 cm −1 ) on a Beckman DU-640 or Cary 300 Bio UV-Vis spectrophotometer. Characterization of ALDH1A1 WT and ALDH1A1 G458N were performed by co-varying acetaldehyde and NAD + concentrations in reactions containing 150 -300 nM enzyme, 50 -500 µM or 20 -200 µM acetaldehyde, and 50 -500 µM NAD + in 50 mM sodium BES, pH 7.5 at 25°C. Reactions were initiated by adding enzyme. Selectivity of compounds for dehydrogenase activity of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1 and ALDH2 were measured in a solution containing 100 -200 nM enzyme, 200 µM NAD + , 1% DMSO, and 100 µM propionaldehyde (non-saturating for all enzymes tested, except ALDH2) in 50 mM sodium BES. ALDH3A1 activity was measured under the following conditions: 25 nM enzyme, 200 µM NAD + , 1% DMSO, and 300 µM benzaldehyde (~K M ) in either 100 mM sodium phosphate buffer, pH 7.5 or 50 mM sodium BES, pH 7.5. All assays were performed at 25°C and were initiated by the addition of the aldehyde substrate following a 2 minute preincubation with compound and cofactor. Selectivity was initially tested using 20 µM compound, with ALDH1A1-selective modulators further tested using 100 µM compound. IC 50 values for propionaldehyde oxidation were calculated by varying the concentration of the compounds from 0 to 200 µM. After a 2 minute pre-incubation with compound and NAD + , all reactions were initiated by the addition of propionaldehyde. Data were fit to the four parameter EC 50 equation using SigmaPlot (StatSys v12.3) . The values represent the average of three independent experiments (each n = 3). The mode of inhibition was determined via steady-state kinetics by co-varying inhibitor and substrate concentrations at fixed concentration of the second substrate. All reactions contained 100-150 nM ALDH1A1 and 1% DMSO in 50 mM sodium BES, pH 7.5 at 25°C. When cofactor NAD + was varied, the reactions contained 200 µM propionaldehyde and 20 -200 µM or 25 -250 µM NAD + (K m = 50 µM). When acetaldehyde was varied, the reactions contained 800 or 1000 µM NAD + and 100 -800 µM acetaldehyde (K m = 180 µM). All data were fit to competitive, noncompetitive, uncompetitive, and mixed inhibition models using both single substratesingle inhibitor or tight binding inhibition programs in SigmaPlot (StatSys v12.3). The appropriate model was selected through analysis of goodness-of-fit and the residuals of those fits. The values represent the average of three independent experiments (each n = 3) using at least two protein preps. In Sigmaplot, the data were best fit to the following equations:
Crystallization and structure determination of ALDH1A1 and its complexes with inhibitors
Crystals of ALDH1A1 at 3-5 mg/mL concentration were equilibrated against a crystallization solution of 100 mM Na + BisTris, pH 6.2-6.8, 8-12% PEG3350 (Hampton Research), 200 mM NaCl, and 5-10 mM YbCl 3 at 25°C. For the enzyme·CM026 and enzyme·CM037 complex, ALDH1A1·N121S was used, while wtALDH1A1 was used for the ALDH1A1·CM053 complex. CM026 and CM053 complexes were prepared by soaking crystals overnight with crystallization solution containing 500 µM inhibitor with 2% (v/v) DMSO. The CM037 complex was prepared by soaking crystals with crystallization solution containing 500 µM inhibitor, 1% (v/v) DMSO, and 1 mM NAD + for 5 hours. Cryoprotection of the crystals for flash-freezing utilized 20% (v/v) ethylene glycol in the ligand soaking solution. Diffraction data were collected at Beamline 19-ID for the ALDH1A1-CM026 complex and Beamline 19-BM for the ALDH1A1-CM053 complex, both operated by the Structural Biology Consortium at the Advanced Photon Source (APS), Argonne National Laboratory. For the ALDH1A1-CM037 complex, data were collected at Beamline 23-ID-D (GM/CA), sponsored by National Institute of General Medical Sciences and National Cancer Institute of the National Institutes of Health at APS. All diffraction data were indexed, integrated, and scaled using either the HKL2000 or HKL3000 program suites 59 . The CCP4 program suite 60 was used for molecular replacement and refinement, using human apoALDH1A1 structure (PDB code 4WJ9) as a model for both structures. The molecular graphics application Coot 61 was used for model building and TLSMD (Translation/Libration/Screw Motion Determination) server was used to determine the appropriate TLS tensors for refinement of the protein 62, 63 . Structural basis of selectivity of CM026 for ALDH1A1. (A) Multiple sequence alignment in the region of ALDH1A1 Gly458 to the mature form of ALDH2. (B) Structure of ALDH1A1 with bound CM026 (blue) compared to ALDH2 (cyan) and ALDH3A1 (grey) indicating that a bulky amino acid such as the Asp of ALDH2 and Ile of ALDH3A1 would clash with CM026 and prevent the compound from inhibiting the enzyme. Sequence alignment was performed using NCBI delta-BLAST while structural alignment was performed using least Selectivity of compounds for WT vs G458N mutant. For CM026 and its analogs, 100 µM of compound was used. For CM037 and CM302, 20 µM of compound was used. Each value is mean/SEM (n=3). Comparison of the active site topography of human ALDH1A1, ALDH2, and ALDH3A1. The three isoenzymes were aligned using LSQ in Coot and the surface figures generated via Pymol. The active site cysteine is shown in red for all three isoenzymes. G458 in ALDH1A1 (PDB Code 4WJ9) and its equivalent residues D457 in ALDH2 (PDB Code ICW3) and I391 in ALDH3A1 (PDB Code 3SZA) are shown in yellow. Comparison of the binding of CM026 to ALDH1A1 (PDB Code 4WP7) with the binding of daidzin to ALDH2 (PDB Code 2VLE). ALDH1A1 is shown in light blue with CM026 in dark blue. ALDH2 is shown in light green with daidzin in dark green. The active site cysteine is shown in red for both isoenzymes. Although both compounds bind in the same location, they bind in a different orientation enabling CM026 to inhibit ALDH1A1 but not ALDH2 due to steric hindrance of D474 (D457 in the mature sequence, in orange), while daidzin inhibits both isoenzymes. Figure generated in Pymol. Table 1 SAR for CM026 Analogs. Table 2 Data collection and refinement statistics. 
